Shots: Just-Evotec to receive $15M up front, milestones on completion of the construction of the J.POD facility (facility of the future) as well as a broad collaboration around reserved capacities […]readmore
Tags : Just – Evotec Biologics
Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” […]readmore
Shots: Biocon Biologics will perform all end-to-end development activities, IND filing, manufacturing and commercialization post-regulatory approval in its own authorized global markets for assets and will utilize Just – Evotec […]readmore